Skip to main content

Januvia FDA Approval History

FDA Approved: Yes (First approved October 17, 2006)
Brand name: Januvia
Generic name: sitagliptin phosphate
Dosage form: Tablets
Company: Merck & Co., Inc.
Treatment for: Diabetes, Type 2

Januvia (sitagliptin phosphate) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Development timeline for Januvia

Oct 17, 2006Approval Januvia Merck & Co., Inc. - Treatment for Type 2 Diabetes
Feb 15, 2006Merck Announces FDA Acceptance of New Drug Application for Januvia, the Company's Investigational Medicine for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.